Carcinoembryonic antigen in patients with urologic cancers.
D000230:Adenocarcinoma / Q000276:immunology / Q000473:pathology / Q000628:therapy; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000473:pathology / Q000628:therapy; D002295:Carcinoma, Transitional Cell / Q000276:immunology / Q000473:pathology / Q000628:therapy; D005260:Female; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D007680:Kidney Neoplasms / Q000276:immunology / Q000628:therapy; D008297:Male; D011471:Prostatic Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy; D011863:Radioimmunoassay; D001749:Urinary Bladder Neoplasms / Q000276:immunology / Q000628:therapy; D014565:Urogenital Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy
D002272:Carcinoembryonic Antigen; D006728:Hormones